Objectives. To assess the concordance of gout management by UK rheumatologists with evidence-based best-practice recommendations.
Introduction
Gout is the most prevalent inflammatory arthritis [1] . However, despite well-understood pathophysiology, readily available effective medications and achievable biochemical treatment targets, treatment remains poor. Only one-third of patients with gout in UK primary care received urate-lowering therapy (ULT) from 1997 to 2012, and only 38% of these achieved a target serum uric acid (SUA) level 4360 mmol/l, despite publication of UK and European management guidelines during this period [16] . Poor uptake occurred even though 44% of patients fulfilled criteria for ULT 1 year after diagnosis and 87% by 5 years [7] . Yet in a recent proof-of-principle study, 92% of patients reached the target level following nurse-led treatment showing that treatment-to-target is achievable [8] .
Less is known about gout management by rheumatologists. A small number of studies from the USA and Europe show that in rheumatology practice, diagnosis is infrequently crystal-proven and initial allopurinol dosing is uncommonly renal function-adjusted, whereas prophylactic colchicine is very commonly co-prescribed with ULT [911] . A target SUA level 4360 mmol/l was achieved in 78% of patients in a study from Ireland but in fewer than half in Spain and the USA [9, 12, 13] .
This national audit aimed to assess the concordance of out-patient gout management by UK rheumatologists with evidence-based recommendations published by the British Society for Rheumatology (BSR) and EULAR and the National Institute for Health and Care Excellence febuxostat technology appraisal 164 [5, 6, 14, 15] .
Methods

Design
All UK rheumatology units were invited to participate in the audit. Data were collected prospectively on all patients with gout, newly referred to rheumatology and seen in out-patient clinics over an 8-week period between 6 May 2013 and 28 June 2013. Anonymized data were collected at the time of consultation and entered onto a webbased proforma housed on a secure server. Units were not compensated for participation but reminders were sent during the audit period to maximize participation. The audit was deemed not to require research ethics approval as per guidance from the NHS Health Research Authority [16] . The audit protocol was reviewed and approved by the BSR Standards, Audit and Guidelines Working Group.
Data collection
The proforma requested information about demographic details (age, gender), method of diagnosis (clinical, radiographic, microscopy of aspirated SF/tophaceous material), clinical features (tophi, number of attacks in the preceding year), comorbidities, current and previous ULT, ULT initiated including starting dose, use of prophylactic drugs (NSAID, colchicine, corticosteroids), diuretic use, blood tests [SUA level, serum creatinine, estimated glomerular filtration rate (eGFR)] and follow-up plan. Follow-up data collected 12 months later included the most recent SUA level (where available).
Audit standards
Audit standards were determined a priori based on the 2006 EULAR recommendations for the diagnosis and management of gout, 2007 BSR guideline for the management of gout and National Institute for Health and Care Excellence febuxostat technology appraisal 164 [5, 6, 14, 15] . Audit standards (AS) pertained to diagnosis (AS1, AS2), diuretic cessation (AS3), indications for ULT (AS4), allopurinol starting dose (AS5, AS6), prophylaxis (AS7), use of uricosuric drugs and febuxostat (AS8), use of febuxostat in patients with heart disease (AS9) and whether target SUA levels were achieved (AS10, AS11) ( Table 1 ).
Statistical analysis
Characteristics of the study sample were described using simple descriptive statistics: mean (S.D.) or median (interquartile range) for continuous variables and frequency (%) for categorical variables. The concordance with each AS was assessed by calculating the frequency (%) of eligible patients fulfilling each audit standard.
Results
Baseline patient characteristics Data were entered for 434 patients from 91 rheumatology departments across the UK, including teaching and district general hospitals. Mean (S.D.) age was 59.8 years (15.1); 356 (82%) were male. Hypertension, renal disease, hyperlipidaemia and heart disease were common ( Table 2) . One hundred and thirty-six patients (31%) were taking allopurinol at the time of their rheumatology appointment, few were taking other ULTs. Diuretics were taken by 106 patients (24%). Mean (S.D.) SUA level was 496 (128) mmol/l. Baseline SUA level was 4360 mmol/l in 65 (15%) and <300 mmol/l in 36 (8%). Median (interquartile range) number of acute attacks of gout in the preceding 12 months was 3 (15).
Audit standards-baseline
AS1: Clinical diagnosis is acceptable and AS2: Definitive diagnosis requires crystal examination
The diagnosis of gout was made on clinical grounds in 362 (83%). One hundred and eight (25%) had clinically evident tophi and 56 (13%) had radiographic features of gout. Diagnosis was based on microscopic identification of monosodium urate crystals in 57 (13%). AS3: In patients on diuretic therapy, this should be stopped or the dose reduced if possible
Of 106 patients taking a diuretic, this was stopped or the dose reduced in 30 (28%). There were 26 patients taking a diuretic who did not have cardiac or renal failure. Of these, the diuretic was stopped or the dose reduced in 15 (58%). AS4: Indications for ULT are two or more attacks over 1 year, gouty tophi, radiographic damage, eGFR <80 ml/min, uric acid renal calculi or continuing diuretic treatment Of 382 patients with at least one indication for ULT, 291 (76%) either continued or were commenced on ULT. For individual indications, the percentages continuing or commencing ULT were: tophi 81% (87 out of 108), two or more attacks in the last year 79% (207/261), eGFR <80 ml/min 74% (157/212), continuing diuretic use 71% (56/79), renal calculi 67% (8/12) and radiographic joint damage 66% (37/56).
AS5: Allopurinol should be started at low dose (50100 mg daily)
One hundred and fifty-eight patients were commenced on allopurinol. The starting daily dose was 50 mg in 10 (6%), 100 mg in 129 (82%), 300 mg in 14 (9%) and unspecified in 5 (3%). AS6: Allopurinol should be started at lower doses in patients with renal impairment Of 42 patients with chronic kidney disease stages 35 (eGFR <60 ml/min) who started allopurinol, the starting daily dose was 50 mg in 7 (17%), 100 mg in 33 (79%) and unspecified in 2 (5%).
Six patients with chronic kidney disease stage 4 or 5 (eGFR <30 ml/min) started allopurinol. Of these, the starting daily dose was 50 mg in 2 (33%), 100 mg in 3 (50%) and unspecified in 1 (17%). AS7: Colchicine or NSAID prophylaxis should be coprescribed at ULT initiation ULT was initiated in 199 patients. Of these, 187 (94%) were co-prescribed prophylaxis. Colchicine was most commonly used (122, 61%) followed by an NSAID (53, 27%), oral corticosteroids (31, 16%) and intramuscular corticosteroids (13, 7%). AS8: Following allopurinol intolerance or inefficacy, treat gout with sulphinpyrazone, benzbromarone, probenecid or febuxostat Sulphinpyrazone was started in two patients, both of whom had previously taken allopurinol. Of four patients started on benzbromarone, three (75%) had previously taken allopurinol. Forty-four patients were commenced on febuxostat. Of these, 37 (84%) had previously taken allopurinol. None was commenced on probenecid. AS9: Febuxostat is not recommended for patients with ischaemic heart disease or congestive cardiac failure Of 44 patients commenced on febuxostat, 8 (18%) had ischaemic heart disease or congestive cardiac failure.
Planned clinic follow-up appointment
A follow-up appointment in rheumatology was proposed for 316 patients (73%). Ninety-two patients (21%) were discharged to primary care. Follow-up was left 'open', to be arranged according to the patient's need, in 23 (5%).
Twelve-month follow-up
Twelve-month follow-up data were received for 219 patients (50%). These patients had tophi at baseline more frequently than those without follow-up data (29% vs 21%) but did not differ by age, gender, number of attacks in the 12 months preceding baseline, previous allopurinol use or baseline SUA level or renal function.
Audit standards-12-month follow-up AS10: Target SUA level is 4360 mol/l and AS11: Target SUA level is <300 mol/l Of 219 patients with 12-month follow-up data, a follow-up SUA level was available for 157 (72%) and not performed in 40 (18%). Whether or not a follow-up SUA level had been checked was unknown in 22 (10%). Of the 197 patients in whom it was known whether a follow-up SUA level was performed, target SUA levels of 4360 and <300 mmol/l were achieved by 89 (45%) and 50 (25%), respectively.
Discussion
In this first national audit of gout management by UK rheumatologists, ULT initiation in patients with indications (AS4), allopurinol starting dose and renal adjustment (AS5, AS6), use of prophylaxis when initiating ULT (AS7) and use of uricosurics and febuxostat (AS8, AS9) concorded well with guidelines [5, 6, 14, 15] . Few patients were diagnosed by monosodium urate crystal identification (AS2). Cessation or reduction of diuretics (AS3) was infrequently recommended, even among patients without cardiac or renal failure. Our most important finding is that target SUA levels 4360 mmol/l (AS10) and <300 mmol/l (AS11) were achieved by only 45 and 25% of patients, respectively. This audit could not ascertain why target levels were infrequently reached but reasons could include patients being discharged, rheumatologists not up-titrating ULT, poor adherence, patient non-attendance for appointments or blood tests, or treatment side-effects.
Our finding that gout diagnosis was based upon crystal identification in only 13% of patients (AS2) is similar to studies undertaken in Spain (26%), and France and Greece (6%) [9, 11] . Most patients initiating allopurinol were dosed appropriately for renal function (AS5, AS6), contrasting with Spain where 52% of patients receiving allopurinol were initiated at low-dose (4100 mg daily) [9] and the USA where 92% of patients with moderate-severe kidney disease starting allopurinol commenced at a dose >50 mg daily [11] . However, renal-adjusted dosing often fails to achieve target SUA levels and a recent randomized trial supports the effectiveness and safety of higher doses [17, 18] . In our study, 94% of patients who commenced ULT were co-prescribed prophylaxis (AS7) similar to the USA (90%), and France and Greece (70%) [10, 11] . The proportion who achieved a target SUA level 4 360 mmol/l was similar to studies from Spain (41%) and the USA (35%), but lower than a rheumatology sub-specialty gout clinic in Ireland (78%) [9, 12, 13] . Compared with audits of management in UK primary care [3, 4] , rheumatologists more frequently initiated ULT when tophi were present (81% versus 20%), started low-dose allopurinol (88% vs 62%) and co-prescribed prophylaxis with ULT (94% vs 25%); however, general practitioners more commonly recommended diuretic cessation/reduction (28% vs 36%). Most importantly, the proportion who achieved a target SUA level 4360 mmol/l was only slightly higher than that achieved in primary care (38% of those treated with allopurinol) [4] .
Strengths of this audit include the national setting and sample size. Patients were entered from most UK rheumatology units. Data were entered at the time of consultation, making accurate recording likely. However, clinicians' awareness of the audit could have influenced clinical behaviour, potentially overestimating guideline concordance. Caveats regarding data collection include not ascertaining whether rheumatologists were trainees or fully trained, or use of ultrasonography or dual-energy CT in diagnosis. Provision of dietary and lifestyle advice was not assessed because many rheumatology units do not routinely quantify dietary intake and body mass index and clear thresholds for intervention are lacking [5, 6, 14] , preventing assessment of the appropriateness of such advice. We asked about renal calculi and radiographic features of gout, rather than specifying uric acid calculi and radiographic damage, potentially under-estimating how many people with these indications received ULT (AS4). Renal calculi (67%) and radiographic damage (66%) were the indications with the lowest proportions receiving ULT. Twelve-month follow-up data were available for only half of the baseline sample, although these differed from those lost-to-follow-up only by having more frequent tophi.
Frequent suboptimal gout management in UK primary care is replicated in rheumatology clinics. Further research should investigate reasons for suboptimal management in rheumatology and examine how best to configure services to facilitate optimum evidence-based ULT. Our experience is that follow-up of patients with gout in rheumatology is very variable, with some rheumatologists anecdotally reporting local commissioning arrangements preventing follow-up of patients with gout. This suggests that our findings reflect suboptimal management in both rheumatology and primary care, indicating that rheumatologists should improve management in secondary care but also work with primary care colleagues to develop better systems to treat gout across the health economy. Subsequent audits should compare against recently updated EULAR and BSR recommendations [19, 20] . Our findings and these new guidelines' recommendation that ULT should be offered to all patients with gout at first diagnosis should serve as a 'call-to-arms' to all rheumatologists to take gout seriously and ensure that ULT is initiated, escalated and monitored appropriately, in order to achieve target SUA levels to benefit patients.
